| Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial MD Tameris, M Hatherill, BS Landry, TJ Scriba, MA Snowden, S Lockhart, ... The Lancet 381 (9871), 1021-1028, 2013 | 1241 | 2013 |
| COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II D Freeman, BS Loe, A Chadwick, C Vaccari, F Waite, L Rosebrock, ... Psychological medicine 52 (14), 3127-3141, 2022 | 860 | 2022 |
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans H McShane, AA Pathan, CR Sander, SM Keating, SC Gilbert, K Huygen, ... Nature medicine 10 (11), 1240-1244, 2004 | 784 | 2004 |
| Rapid Detection of Mycobacterium tuberculosisInfection by Enumeration of Antigen-specific T Cells A Lalvani, AA Pathan, H Mcshane, RJ Wilkinson, M Latif, CP Conlon, ... American journal of respiratory and critical care medicine 163 (4), 824-828, 2001 | 767 | 2001 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, HJC McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 583 | 2021 |
| Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect … AA Pathan, KA Wilkinson, P Klenerman, H McShane, RN Davidson, ... The Journal of Immunology 167 (9), 5217-5225, 2001 | 492 | 2001 |
| Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a … NP Goonetilleke, H McShane, CM Hannan, RJ Anderson, RH Brookes, ... The Journal of Immunology 171 (3), 1602-1609, 2003 | 475 | 2003 |
| Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults B Killingley, AJ Mann, M Kalinova, A Boyers, N Goonawardane, J Zhou, ... Nature Medicine 28 (5), 1031-1041, 2022 | 471 | 2022 |
| Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice EK Forbes, C Sander, EO Ronan, H McShane, AVS Hill, PCL Beverley, ... The Journal of Immunology 181 (7), 4955-4964, 2008 | 357 | 2008 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 356 | 2022 |
| Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for … H McShane, R Brookes, SC Gilbert, AVS Hill Infection and immunity 69 (2), 681-686, 2001 | 322 | 2001 |
| T-cell activation is an immune correlate of risk in BCG vaccinated infants HA Fletcher, MA Snowden, B Landry, W Rida, I Satti, SA Harris, ... Nature communications 7 (1), 11290, 2016 | 318 | 2016 |
| Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis HM Vordermeier, B Villarreal-Ramos, PJ Cockle, M McAulay, SG Rhodes, ... Infection and immunity 77 (8), 3364-3373, 2009 | 314 | 2009 |
| Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial D Freeman, BS Loe, LM Yu, J Freeman, A Chadwick, C Vaccari, ... The Lancet Public Health 6 (6), e416-e427, 2021 | 293 | 2021 |
| Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte … NER Beveridge, DA Price, JP Casazza, AA Pathan, CR Sander, TE Asher, ... European journal of immunology 37 (11), 3089-3100, 2007 | 292 | 2007 |
| Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells TJ Scriba, M Tameris, N Mansoor, E Smit, L van der Merwe, F Isaacs, ... European journal of immunology 40 (1), 279-290, 2010 | 270 | 2010 |
| A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara … M Mwau, I Cebere, J Sutton, P Chikoti, N Winstone, EGT Wee, T Beattie, ... Journal of general virology 85 (4), 911-919, 2004 | 262 | 2004 |
| MVA. 85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques FAW Verreck, RAW Vervenne, I Kondova, KW van Kralingen, ... PloS one 4 (4), e5264, 2009 | 260 | 2009 |
| Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa T Hawkridge, TJ Scriba, S Gelderbloem, E Smit, M Tameris, S Moyo, ... The Journal of infectious diseases 198 (4), 544-552, 2008 | 227 | 2008 |
| The human immune response to tuberculosis and its treatment: a view from the blood JM Cliff, SHE Kaufmann, H McShane, P van Helden, A O'Garra Immunological reviews 264 (1), 88-102, 2015 | 223 | 2015 |